UNSPSC 51141579: Stiripentol

This classification denotes an anticonvulsant with the molecular formula C14H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R02XOT8V8I, chemically known as 4,4-dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol but generally known as stiripentol, which bears US NIH Compound Identifier 5311454. European Medicines Agency schedules Stiripentol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10654MIG.

UNSPSC 51141579 Stiripentol, a Commodity code, shows minimal alignment with actual state and local procurement activity in the available record. The single recent opportunity tagged to this code—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—does not concern stiripentol, an anti-seizure medication with a narrow clinical indication. Instead, the solicitation addresses naloxone (opioid-reversal medication) and drug deactivation equipment, both acquired for community health and harm-reduction purposes, not for the neurological condition stiripentol treats. The code appears to be a data-entry error or misclassification by the issuing body rather than a reflection of genuine procurement demand under this commodity classification.

The sole record shows Seminole County, Florida posting an IFB on June 30, 2026 (with a due date of July 26, 2023 in the record—a date inconsistency suggesting data quality issues) for 1,900 units of naloxone and 800 safe drug deactivation systems on an annual basis, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with one-year renewal option. Given the scope mismatch between the code name and the work being solicited, no meaningful market activity or repeat-buyer patterns emerge from this code at this time. Business development professionals should treat this code as inactive for state and local procurement purposes and verify the correct UNSPSC classification for any future naloxone or drug-deactivation-system opportunities.